The iFuse system has been cleared by the US Food and Drug Administration (FDA) to include a statement that “Clinical studies have demonstrated that treatment with the iFuse Implant System improved pain, patient function and quality of life at 12 months post-implantation” according to manufacturer SI-Bone.
The new full indication for use statement is: “The iFuse Implant System is intended for sacroiliac fusion for conditions including sacroiliac joint dysfunction that is a direct result of sacroiliac joint disruption and degenerative sacroiliitis. This includes conditions whose symptoms began during pregnancy or in the peripartum period and have persisted postpartum for more than six months. Clinical studies have demonstrated that treatment with the iFuse Implant System improved pain, patient function, and quality of life at 12-months post-implantation.”
”We are pleased with the FDA’s review of our clinical data supporting this 510(k) clearance and look forward to additional filings as SI-Bone continues to conduct studies and follow-up on patients treated with the iFuse Implant System. Data supporting these claims came from retrospective and prospective studies, including INSITE (Investigation of Sacroiliac Fusion Treatment; 148 patients), SIFI (Sacroiliac Joint Fusion with iFuse Implant System; 172 patients) and additional studies reviewed by the Agency,” said Roxanne Dubois, vice president of quality and regulatory affairs at SI-Bone.
“Over twenty clinical studies demonstrating safety and effectiveness with the iFuse Implant System have been published in peer-reviewed journals including studies with follow up out to as much as five years. Over 18,000 iFuse procedures have been performed worldwide making it the leading minimally invasive solution for these patients,” commented Jeff Dunn, president and CEO of SI-Bone.
